# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

K180971 B. Purpose for Submission: Addition of optional Fecal Extraction Device (FED) sample collection assay C. Measurand: Fecal Calprotectin D. Type of Test: Quantitative chemiluminescent microparticle-enhanced immunoassay E. Applicant: Inova Diagnostics, Inc. F. Proprietary and Established Names: QUANTA Flash Calprotectin Reagents Fecal Extraction Device G. Regulatory Information:

1. Regulation section: 866.5180 ‒ Fecal calprotectin immunological test system

2. Classification: Class II

3. Product code: NXO ‒ Fecal calprotectin immunological test system

4. Panel: (82) Immunology

# H. Intended Use:

1. Intended use:

The Fecal Extraction Device is a single use tube containing extraction buffer intended for sampling and extracting human stool specimens and subsequent analysis with the QUANTA Flash Calprotectin assay.

2. Indication for use: Same as intended use

3. Special conditions for use statement: Prescription use only

4. Special instrument requirements:

The FED has only been evaluated for use with the QUANTA Flash Calprotectin IVD system. The QUANTA Flash Calprotectin IVD is for use with the BIO-FLASH chemiluminescence detection instrument.

# I. Device Description:

The optional Fecal Extraction Device (FED) acquires the amount of stool necessary to perform the QUANTA Flash Calprotectin assay directly from the primary specimen container instead of weighing the sample.

The device consists of a tube containing $2 . 8 \mathrm { m L }$ of extraction buffer, and a stick shaped with seven grooves for collecting the sample. The upper end of the device is made up of two parts which can be removed with two separate rotations: the white screw cap (connected to the plastic stick with grooves) is removed by twisting counter-clockwise. The red lower part (for retaining the excess material) is removed by twisting clockwise. Once having completed the extraction procedure, remove both the white and red upper parts. The tube containing the extracted sample can be placed directly into the BIO-FLASH instrument sample rack.

# J. Substantial Equivalence Information:

1. Predicate device name(s): QUANTA Flash Calprotectin Reagents, Controls, Calibrators

2. Predicate 510(k) number(s): K170993

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate (K170993)</td></tr><tr><td rowspan=1 colspan=1>Assay methodology</td><td rowspan=1 colspan=1>Solid phase chemiluminescentimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Extracted human stool</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>milligram of calprotectin perkilogram of stool (mg/kg)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalyticalMeasuring Range(AMR)</td><td rowspan=1 colspan=1>16.1 - 3500.0 mg/kg</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Lot-specific Master Curve + threecalibrators</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Capture antibody</td><td rowspan=1 colspan=1>Polyclonal rabbit anti-calprotectin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detectionantibody/Conjugate</td><td rowspan=1 colspan=1>Isoluminol-conjugaed monoclonalanti-calprotectin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Kit Shelf life</td><td rowspan=1 colspan=1>One year</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The Fecal Extraction Device is asingle use tube containingextraction buffer intended forsampling and extracting humanstool specimens and subsequentanalysis with the QUANTA FlashCalprotectin assay.</td><td rowspan=1 colspan=1>QUANTA Flash Calprotectin is achemiluminescent immunoassay forthe quantitative determination offecal calprotectin in extractedhuman stool samples. Elevatedlevels of fecal calprotectin, inconjunction with clinical findingsand other laboratory tests, can aidin the diagnosis of inflammatorybowel disease (IBD) (ulcerativecolitis and Crohn&#x27;s disease), and inthe differentiation of IBD fromirritable bowel syndrome (IBS).</td></tr><tr><td rowspan=1 colspan=1>Specimen sampling</td><td rowspan=1 colspan=1>Unitized specimen probe andsample extraction device withextraction buffer</td><td rowspan=1 colspan=1>Manual weighing of fecal sampleinto extraction buffer</td></tr><tr><td rowspan=1 colspan=1>Samplenormalization</td><td rowspan=1 colspan=1>Volumetric</td><td rowspan=1 colspan=1>Sample weight</td></tr><tr><td rowspan=1 colspan=1>Extraction Shelf Life</td><td rowspan=1 colspan=1>Two years</td><td rowspan=1 colspan=1>Not applicable</td></tr></table>

# K. Standard/Guidance Document Referenced:

<table><tr><td rowspan=1 colspan=1>Org</td><td rowspan=1 colspan=1>Standard ID</td><td rowspan=1 colspan=1>Version</td><td rowspan=1 colspan=1>Date</td><td rowspan=1 colspan=1>Title</td></tr><tr><td rowspan=1 colspan=1>CLSI</td><td rowspan=1 colspan=1>EP05</td><td rowspan=1 colspan=1>A3</td><td rowspan=1 colspan=1>Sep 2014</td><td rowspan=1 colspan=1>Evaluation of Precision Performance ofQuantitative Measurement Methods</td></tr></table>

# L. Test Principle:

The optional FED collects the amount of stool used to perform the QUANTA Flash Calprotectin assay directly from a primary specimen container instead of manually weighing the sample. The FED also contains buffer for extraction of the sample. Following extraction with the FED, the sample can be used for the QUANTA Flash Calprotectin assay procedure, per K170993.

The principle of the assay is chemiluminescent microparticle immunoassay, a variation of solid phase immunoassay. The QUANTA Flash Calprotectin assay is designed to run on the BIOFLASH instrument, which automatically processes the samples, runs the assay and reports the results.

# M. Performance Characteristics:

1. Analytical performance:

All parameters met the manufacturer’s pre-established acceptance criteria.

a. Precision/Reproducibility:

# FED Validation

The manufacturer performed a study evaluating the reproducibility of sample collection by the FED probe. Five stool specimens ranging from 2‒5 on the Bristol Stool Form Scale (BSFS) were sampled by three operators with five replicates per sample per operator. Samples on the FED were weighed against the empty weight of the FED. Results of the study are summarized below:

<table><tr><td rowspan=1 colspan=6>Precision of FED sample weight</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>BSFS</td><td rowspan=1 colspan=1>Sample Weight(Mean ±SD)</td><td rowspan=1 colspan=1>Repeatability%CV</td><td rowspan=1 colspan=1>Between-Operator %CV</td><td rowspan=1 colspan=1>Within-Laboratory %CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>54.7 ± 3.6 mg</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6.8%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>56.9 ± 3.7 mg</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>55.6 ± 3.4 mg</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>57.7 ± 4.4 mg</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>55.2 ± 3.7 mg</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>7.1%</td></tr></table>

Repeatability of sample collection weight was assessed across all five samples, replicates and operators. The sample weight collected by the FED is described in the table below:

<table><tr><td colspan="2" rowspan="1">Sample collection performance of FED</td></tr><tr><td colspan="1" rowspan="1">Mean Sample Weight</td><td colspan="1" rowspan="1">56.0 mg</td></tr><tr><td colspan="1" rowspan="1">Median Sample Weight</td><td colspan="1" rowspan="1">56 mg</td></tr><tr><td colspan="1" rowspan="1">Range</td><td colspan="1" rowspan="1">50 - 62 mg</td></tr><tr><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">55- 57 mg</td></tr><tr><td>Std Dev</td><td>±3.8 mg</td></tr><tr><td>%CV</td><td>6.9%</td></tr></table>

# Assay Precision

The sponsor performed a precision study, based on CLSI EP05-A3.

To study precision, eight stool samples representing the span of the analytical measuring range (AMR) were extracted using the FED and tested once per day $\times$ five replicates $\times$ five days $\times$ three operators, for a total of 75 measurements per sample. Each FED extraction was performed daily by each operator independently. The results of this study are summarized below:

<table><tr><td rowspan=1 colspan=12>Fecal calprotectin reproducibility, using the fecal extraction device</td></tr><tr><td rowspan=2 colspan=1>MeanfCal(mg/kg)</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Operator</td><td rowspan=1 colspan=2>Between-Operator</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>29.5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>24.4%</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>25.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>25.4%</td></tr><tr><td rowspan=1 colspan=1>40.0</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>15.0%</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>16.1%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>17.0%</td></tr><tr><td rowspan=1 colspan=1>53.2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>10.2%</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>10.9%</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>14.1%</td></tr><tr><td rowspan=1 colspan=1>108.2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>8.4%</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>10.8%</td></tr><tr><td rowspan=1 colspan=1>222.9</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>20.9</td><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>22.1</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>10.2%</td></tr><tr><td rowspan=1 colspan=1>535.4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>41.2</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>44.1</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>21.9</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>49.2</td><td rowspan=1 colspan=1>9.2%</td></tr><tr><td rowspan=1 colspan=1>1278.3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>45.0</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>114.6</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>123.2</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>123.5</td><td rowspan=1 colspan=1>9.7%</td></tr><tr><td rowspan=1 colspan=1>1560.0</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>63.9</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>197.1</td><td rowspan=1 colspan=1>12.6%</td><td rowspan=1 colspan=1>207.2</td><td rowspan=1 colspan=1>13.3%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>207.2</td><td rowspan=1 colspan=1>13.3%</td></tr></table>

The manufacturer has included a statement in the labeling alerting users that the assay may have greater imprecision when used with the FED, as compared to the predicate manual weighing method.

b. Linearity/assay reportable range:

Assay linearity was evaluated in K170993.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Sample Stability

Sample stability was evaluated using seven stool samples selected to span the AMR, with particular attention to the equivocal range (Eq): $5 0 { - } 1 2 0 \ \mathrm { m g / k g }$ fCal. Samples were extracted using the FED and tested in duplicate with the QUANTA Flash fCal assay for up to 73 hours stored at room temperature, up to 21 days stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ , and after up to five cycles of freeze-thaw. All results met the manufacturers prespecified acceptance criteria.These results support the manufacturer’s recommendation for sample storage up to 72 hours at room temperature, up to 14 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ , and up to four freeze-thaw cycles.

# FED Shelf-Life Stability

Real-time stability was evaluated to determine shelf-life for the FED. pH values for the extraction buffer in the device were assessed on three lots every 3‒6 months for a total of 24‒26 months. pH values varied less than $5 \%$ within the timespan of the study.

The stability of the FED was evaluated using fCal assay values as a performance output. Fifteen stool samples selected to span the AMR were extracted using the FED from two lots at expiration date, and one newly produced FED lot for comparison. From these extracted samples, fCal values were tested with the QUANTA Flash fCal assay. These results support the manufacturer’s recommendation for FED expiration date up to two years.

FED Stability: Room Temperature Storage

Three independent lots of FED were evaluated for room temperature stability. Six stool samples, selected to span the AMR, were extracted using FED devices stored at room temperature for up to 73 hours, as compared to FED devices stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ during this interval. From these extracted samples, fCal values were tested with the QUANTA Flash fCal assay. These results support the manufacturer’s recommendation for FED storage at room temperature up to 72 hours.

d. Detection limit: Assay detection capabilities was evaluated in K170993.   
e. Analytical specificity: Assay analytical specificity was evaluated in K170993.   
f. Assay cut-off: Assay cutoff was evaluated in K170993.

2. Comparison studies:

# a. Method comparison with predicate device:

Ninety-seven (97) human stool samples selected to represent the span of the AMR were extracted by the FED as well as by the manual weighing method of the predicate device. Samples from both processing methods were tested in singlicate by the QUANTA Flash fCal assay. Linear regression by Passing-Bablok is summarized below:

<table><tr><td rowspan=1 colspan=2>Method Comparison performance of FED versus manual extraction</td></tr><tr><td rowspan=1 colspan=1>Slope (95%CI)</td><td rowspan=1 colspan=1>0.93 (0.821.06)</td></tr><tr><td rowspan=1 colspan=1>Intercept (95%CI</td><td rowspan=1 colspan=1>-1.2 (-9.76.4)</td></tr><tr><td rowspan=1 colspan=1>Bias at 120 mg/kg fCal</td><td rowspan=1 colspan=1>-7.8% (-16.0%-0.6%)</td></tr><tr><td rowspan=1 colspan=1>$R^{}$</td><td rowspan=1 colspan=1>0.975</td></tr></table>

Qualitative agreement measures derived from the FED were compared to the manual weighing method to evaluate the comparative performance of the FED. Per FDA Guidance, “Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests”, the positive percent agreement (PPA) and negative percent agreement (NPA) were calculated with equivocal results considered positive as well as negative.

<table><tr><td rowspan=1 colspan=6>Qualitative performance of FED extracted samples compared tomanually-weighed samples</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Predicate (Manual)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>fCal(+)</td><td rowspan=1 colspan=1>fCal(Eq)</td><td rowspan=1 colspan=1>fCal(-)</td></tr><tr><td rowspan=3 colspan=1>FED</td><td rowspan=1 colspan=1>fCal(+)</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>fCal(Eq)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>fCal()</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>97</td></tr></table>

<table><tr><td rowspan=2 colspan=1>fCal(Eq) consideredpositive (+)</td><td rowspan=1 colspan=1>PPA (95%CI)</td><td rowspan=1 colspan=1>93.2%(85.197.1%)</td></tr><tr><td rowspan=1 colspan=1>NPA(95%CI)</td><td rowspan=1 colspan=1>87.0%(67.9-95.5%)</td></tr><tr><td rowspan=2 colspan=1>fCal(Eq) considerednegative ()</td><td rowspan=1 colspan=1>PPA(95%CI</td><td rowspan=1 colspan=1>93.5%(82.597.8%)</td></tr><tr><td rowspan=1 colspan=1>NPA(95%CI)</td><td rowspan=1 colspan=1>94.1% (84.198.0%)</td></tr></table>

# b. Matrix comparison:

Human stool is the only claimed matrix. Variations in human stool consistency according to the BSFS index are represented as an independent variable in Precision and Method Comparison studies.

3. Clinical studies: Clinical performance of the fecal calprotectin assay was evaluated in K170993.

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

Reference range and expected values of the fecal calprotectin assay were evaluated in K170993

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.